The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | AVENUE final analysis supports frontline avelumab in Hodgkin lymphoma
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the final 3-year results from the AVENUE study (NCT03617666) evaluating avelumab in frontline classical Hodgkin lymphoma. He highlights the strong progression-free and overall survival outcomes achieved with this PD-L1 inhibitor-based approach, while also reflecting on the evolving role of immunotherapy combinations in Hodgkin lymphoma treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
